• Karen Jui Lin Choo, F Estelle R Simons, and Aziz Sheikh.
• Primary Care Research & Development, Centre for Population Health Sciences: GP section. The University of Edinburgh, Medical School, Doorway 3, Teviot Place, Edinburgh, UK, EH8 9AG.
• Cochrane Db Syst Rev. 2010 Jan 1(3):CD007596.

BackgroundAnaphylaxis is a serious hypersensitivity reaction that is rapid in onset and may result in death. Anaphylaxis guidelines recommend glucocorticoids for the treatment of people experiencing anaphylaxis.ObjectivesWe sought to assess the benefits and harms of glucocorticoid treatment during episodes of anaphylaxis.Search StrategyWe searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, Issue 3), MEDLINE (Ovid) (1966 to September 2009), EMBASE (Ovid) (1988 to September 2009), CINAHL (EBSCOhost) (to September 2009) and The Science Citation Index Expanded (SCI-EXPANDED) (1945 to September 2009). We also searched the UK National Research Register and websites listing ongoing trials, and contacted international experts in anaphylaxis in an attempt to locate unpublished material.Selection CriteriaWe included randomized and quasi-randomized controlled trials comparing glucocorticoids with any control (either placebo, adrenaline (epinephrine), an antihistamine, or any combination of these).Data Collection And AnalysisTwo authors independently assessed articles for inclusion.Main ResultsWe found no studies that satisfied the inclusion criteria.Authors' ConclusionsWe are, based on this review, unable to make any recommendations for the use of glucocorticoids in the treatment of anaphylaxis.

5 keywords...

hide…